NCT06144697: A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants |
|
|
| Recruiting | 1 | 132 | US | BMS-986465, Placebo, Pegasys, Famotidine | Bristol-Myers Squibb | Healthy Participants | 03/25 | 03/25 | | |
| Withdrawn | 1 | 21 | US | Cemiplimab-Rwlc, Libtayo, PEG-IFN alfa-2a, PEGASYS | Baptist Health South Florida, Regeneron Pharmaceuticals | Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma | 07/26 | 07/28 | | |